The Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: ReoPro)-Coated Stent in Acute Myocardial Infarction

Serruys, 1994, A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary heart disease, N Engl J Med, 331, 489, 10.1056/NEJM199408253310801 Kastrati, 2005, Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease, JAMA, 294, 819, 10.1001/jama.294.7.819 Morice, 2002, A randomized comparison of a sirolimus-eluting stent with standard stent for coronary revascularization, N Engl J Med, 346, 1773, 10.1056/NEJMoa012843 Moussa, 2004, Impact of sirolimus-eluting stents on outcome in diabetic patients, Circulation, 109, 2273, 10.1161/01.CIR.0000129767.45513.71 Degertekin, 2004, Very long sirolimus-eluting stent implantation for de novo coronary lesions, Am J Cardiol, 93, 826, 10.1016/j.amjcard.2003.12.018 Lemos, 2004, Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients, Circulation, 109, 1366, 10.1161/01.CIR.0000121358.26097.06 Schofer, 2003, Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries, Lancet, 362, 1093, 10.1016/S0140-6736(03)14462-5 1994, Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, N Engl J Med, 330, 956, 10.1056/NEJM199404073301402 1997, Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization, N Engl J Med, 336, 1689, 10.1056/NEJM199706123362401 1997, Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina, Lancet, 349, 1429, 10.1016/S0140-6736(96)10452-9 1998, Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non–Q-wave myocardial infarction, N Engl J Med, 338, 1488, 10.1056/NEJM199805213382102 Tam, 1998, Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v) beta3 integrins, Circulation, 98, 1085, 10.1161/01.CIR.98.11.1085 Reverter, 1996, Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 Fab treatment of an acute thrombosis and “clinical restenosis”, J Clin Invest, 98, 863, 10.1172/JCI118859 Shappel, 1990, Mac-1 (CD11b/CD8) mediates adherence-dependent hydrogen peroxide production by human and canine neutrophils, J Immunol, 144, 2702, 10.4049/jimmunol.144.7.2702 Simon, 1997, 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1, Thromb Vasc Biol, 17, 528, 10.1161/01.ATV.17.3.528 Mickelson, 1999, Chimeric 7E3 Fab (ReoPro) decreases detectable CD IIb on neutrophils from patients undergoing coronary angioplasty, J Am Coll Cardiol, 33, 97, 10.1016/S0735-1097(98)00532-4 Lefkovits, 1996, Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease, Eur Heart J, 17, 9, 10.1093/oxfordjournals.eurheartj.a014698 Hong, 2004, Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries, Am J Cardiol, 94, 1050, 10.1016/j.amjcard.2004.06.066 Jeong, 2000, ReoPro-coated stent inhibits porcine coronary stent thrombosis and restenosis, Circulation, 102, II666 Lincoff, 2000, Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization, Circulation, 104, 163, 10.1161/01.CIR.104.2.163 Schwarz, 2002, The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alpha(M)beta(2)), Thromb Res, 107, 121, 10.1016/S0049-3848(02)00207-4 Grines, 1999, Coronary angioplasty with or without stent implantation for acute myocardial infarction, N Engl J Med, 341, 1949, 10.1056/NEJM199912233412601 Stone, 2002, Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction; Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators, N Engl J Med, 346, 957, 10.1056/NEJMoa013404 Saia, 2003, Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction, Circulation, 108, 1927, 10.1161/01.CIR.0000096053.87580.CD Lemos, 2004, Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction, J Am Coll Cardiol, 43, 704, 10.1016/j.jacc.2003.12.022 Jeremias, 2004, Stent thrombosis after successful sirolimus-eluting stent implantation, Circulation, 109, 1930, 10.1161/01.CIR.0000127105.99982.21